Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines

Jiale Wang^{1

2}, Tianyu Qiu^{1

2}, Shengxiang Ren^{1

2}

Affiliations

¹ School of Medicine, Tongji University, Shanghai 200331, China.
² Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.

Editorial

Jiale Wang et al. Cancer Biol Med. 2025.

. 2025 Feb 24;22(2):77-82.

doi: 10.20892/j.issn.2095-3941.2024.0497.

Jiale Wang^{1

2}, Tianyu Qiu^{1

2}, Shengxiang Ren^{1

2}

¹ School of Medicine, Tongji University, Shanghai 200331, China.
² Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.

No abstract available

Conflict of interest statement

No potential conflicts of interest are disclosed.

1. Lu S, Zhou J, Jian H, Wu L, Cheng Y, Fan Y, et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir Med. 2023;11:905–15. - PubMed
1. Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, et al. Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M-mutated NSCLC that had progressed after prior EGFR tyrosine kinase inhibitor therapy: a phase 2, multicenter, single-arm, open-label study. J Thorac Oncol. 2022;17:1192–204. - PubMed
1. Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935–48. - PubMed
1. Lu S, Cho BC, Lee JS, Lee SH, Danchaivijitr P, Liu B, et al. LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis. Ann Oncol. 2023;34:S1661.
1. Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair MJ, et al. 507O EXCLAIM-2: phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) + locally advanced/metastatic NSCLC. Ann Oncol. 2023;34:S1663–4.